• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·US·Technology·AIFF
Share

Firefly Neuroscience, Inc. Stocks

$ 1.3Last Updated 05.10.2026

Issuer Rating

2/7
Performance

Modest

Risk

High

Recommendation

Sell

Market Cap

$ 20.12M

$ 1.3
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very low or no dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Latest news

28.09.2026 16:02

Brain-scan firm Firefly to promote partner pediatric ADHD treatment; stock soars 70%

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Based in Toronto, Canada, Firefly Neuroscience, Inc. is a medical technology and artificial intelligence firm specializing in developing neuroscientific solutions. The company's primary goal is to enhance patient outcomes for individuals affected by mental illnesses and neurological disorders. Its flagship product, Brain Network Analytics, is a sophisticated software platform engineered to aid in the diagnosis and treatment of a diverse range of cognitive and psychiatric conditions. These conditions encompass, but are not limited to, depression, dementia, anxiety disorders, concussions, and attention-deficit/hyperactivity disorder. Firefly Neuroscience, Inc. caters to both pharmaceutical companies and medical practitioners.

Company Valuation

Slightly overvalued
3/7

From both historical and forecast perspectives, the stock is slightly overpriced compared to similar stocks.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

13.10.2026 03:00

BofA Identified Three Risks for Apple if SpaceX Becomes a Mobile Carrier

13.10.2026 02:01

Meta has released a new AI model, Muse Wonder, and announced that it has caught up with industry leaders

13.10.2026 01:16

Microsoft could deploy over a million of its own AI chips in 2027, challenging Nvidia

13.10.2026 00:39

Walmart's stock is outperforming luxury stocks. Why might this signal an upcoming Fed rate cut?

12.10.2026 23:19

LVMH fashion and leather sales disappoint in 3Q due to demand slowdown in China

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026